Oligorecurrence Non–small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography–Guided 125I Seed Implantation vs. Second-Line Chemotherapy

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2020.00470
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Rechallenge With First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer

Case Reports in Oncology
Oncology
2018English

Egfr Test-Guided Erlotinib Versus Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Budget Impact Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

P1.01-111 EGFR Exon20 Insertion Patients Treated With First-Line Chemotherapy in Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy

BMJ Open
Medicine
2015English

Phase II Study of Gemcitabine Plus Oxaliplatin as First-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2005English

Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Network Meta-Analysis

Immunotherapy
OncologyAllergyImmunology
2019English

Treatment Results Including More Than Third-Line Chemotherapy for Patients With Advanced Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2010English

Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared With Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer

PLoS ONE
Multidisciplinary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy